TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 21
- 0 vs. Q3 2022
- Portfolio value
- $566.6M
- +$233.2M (+69.9%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ISEEIVERIC bio, Inc. | COM | 5,141,118 | $110.1M | 19.4% | +1,263,215+32.6% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 288,054 | $83.6M | 14.8% | +258,054+860.2% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 3,631,042 | $42.0M | 7.4% | +150,000+4.3% | Added | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 5,905,400 | $37.0M | 6.5% | 00.0% | Unchanged | History |
| GERNGeron Corp | COM | 15,187,073 | $36.8M | 6.5% | +3,071,147+25.3% | Added | History |
| SLNSilence Therapeutics plc | ADS | 2,104,875 | $32.1M | 5.7% | 00.0% | Unchanged | History |
| JBIOJade Biosciences, Inc. | COM | 1,081,274 | $31.7M | 5.6% | +121,702+12.7% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 983,610 | $28.7M | 5.1% | −180,390−15.5% | Reduced | History |
| VTYXVentyx Biosciences, Inc. | COM | 787,231 | $25.8M | 4.6% | +787,231 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 3,395,495 | $23.0M | 4.1% | +3,395,495 | New | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 2,333,300 | $20.2M | 3.6% | +2,333,300 | New | – |
| ACRSAclaris Therapeutics, Inc. | COM | 1,144,939 | $18.0M | 3.2% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 1,423,642 | $17.7M | 3.1% | +75,000+5.6% | Added | History |
| IMVTImmunovant, Inc. | COM | 854,853 | $15.2M | 2.7% | +854,853 | New | History |
| TYRATyra Biosciences, Inc. | COM | 1,989,103 | $15.1M | 2.7% | +1,043,396+110.3% | Added | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 1,000,000 | $10.5M | 1.9% | 00.0% | Unchanged | History |
| TRDAEntrada Therapeutics, Inc. | COM | 584,955 | $7.91M | 1.4% | −57,234−8.9% | Reduced | History |
| MRUSMerus N.V. | COM | 300,000 | $4.64M | 0.8% | 00.0% | Unchanged | History |
| CABACabaletta Bio, Inc. | COM | 486,795 | $4.50M | 0.8% | +486,795 | New | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 253,069 | $1.86M | 0.3% | −1,500−0.6% | Reduced | History |
| ELEVElevation Acquisition Group Inc. | COM | 288,390 | $274.0K | <0.1% | −266,610−48.0% | Reduced | History |
Sold out since Q3 2022 (5)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| ALLKAllakos Inc. | COM | 1,643,500 | $10.1M | 3.0% | History |
| AKUSAkouos, Inc. | COM | 1,350,006 | $9.13M | 2.7% | History |
| TNGXTango Therapeutics, Inc. | COM | 1,172,250 | $4.24M | 1.3% | History |
| DNTHDianthus Therapeutics, Inc. | COM | 2,124,122 | $3.00M | 0.9% | History |
| ZLABZai Lab Ltd | ADR | 72,777 | $2.49M | 0.7% | History |